This study prospectively evaluates whether the use of iCAGES (integrated CAncer GEnome Score) tool in guiding the treatment of advanced cancers is superior to current standard care or IHC-guided therapy in progress free survival (PFS),overall survival (OS),and improvement of life quality.
Pathological and clinical diagnosis of recurrence / metastatic lung cancer or other advanced cancers.
There are PACS images available at the Second Affiliated Hospital of Guangzhou Medical University and the collaborated Hospitals.
The patient is informed consent and signed a written consent.
Age > 70 or <18 years old.
Previous history of malignant tumors.
Pregnant or lactating female patients.
Any serious concomitant disease that is expected to have an adverse effect on prognosis, including the heart disease that treatment is required, unsatisfactory controlled diabetes and psychiatric disorders.
In this study, all the patients will be recruited from the Second Affiliated Hospital of Guangzhou Medical University and the collaborated Hospitals during 01/07/2017 to 01/07/2019, 250 advanced patients (90 cases for A group, 70 cases for B group, and 90 cases for C group) are anticipated to be collected. All the patients are more than 18 years old and less than 75 years old. The follow-up will be performed every 2 month until 2 years after the first treatment post-recruitment or quit.
Case-control
Prospective
inhibitors, ADC drugs such as tarceva, capmatinib, padcev et al for A/C group.
DrugChoose appropriate targeted drugs according to NGS/IHC results.
PFS
The PFS will be recorded during the follow up time.
OS
The OS will be recorded during the follow up time.
Quality of life.
Physicians Global Assessment to measure quality of life
Pain
Visual Analog Score for pain
Click on the lead sponsor to view all of their trials.
Second Affiliated Hospital of Guangzhou Medical University
Lead sponsor
The First Affiliated Hospital of Guangzhou Medical University
Collaborator
Sun Yat-sen University
Collaborator
